ci report adj ep ahead opco/
street consensu estim beat larg driven global
healthcar gener segment incom opco/street
driven out-performance mcr vs opco
gov mcr vs opco due strong beat cigna
rais ep guidanc prior almost
increas come global health
manag also reduc industry-lead cost-trend outlook
bp vs prior follow quarter rais ep estim
price target
recap global healthcar gener segment incom opco/
street mcr opco
gov mcr opco drive strength global supp
vs opco/street group vs opco/street
modestli contribut out-performance
updat guidanc rais ep guidanc
prior driven global hc
benefit reduct bp commerci gov mcr cost
trend furthermor ci rais global supp outlook
maintain group outlook
remain optimist around esrx deal despit recent nois around
deal manag remain confid pass sharehold vote august
compani also reiter accret mid-teen
ep target last manag pleas esrx result
issu wednesday note compani high retent rate
discuss pbm outlook compani discuss addit data
point regard esrx includ roughli half custom transpar
arrang manag also reiter comment came esrx
wednesday compani pass purchas discount price
reduct rebat back custom
conclus overal ci produc anoth robust quarter continu
believ patient investor reward hold name outlook
around esrx gain clariti maintain outperform rate would continu
buyer
provid health care relat
benefit us intern
compani offer insur self-
health vision plan well
disabl life insur product
analyst certif import disclosur see disclosur
capit deploy contribut moder growth
medicar busi growth margin acceler
expos strong growth area healthcar also
avoid mani risk strong rel concentr
aso busi compani also strong track record
growth recent year tradit trade discount
peer although posit neg
express script deal believ compani balanc
sheet ripe take leverag highli accret deal
pay strong long-term return result rate stock
guidanc issu updat
signific uptick util
disabl life busi continu face volatil
exchang busi turn materi loss
price target base combin two methodolog dcf valuat base beta
termin growth rate wacc estim ebitda price-to-earnings target repres
ep estim conserv discount group current trade uncertainti around
express script sort
includ healthcar reform federal/st regul chang cost trend intern busi risk
premium fee
global care benefit expens
healthcar premium
health care benefit expens settlement
premium fee
total benefit expens
premium fee
oper expens revenu
pharmaci cost good sold
total benefit expens
incom attribut non-controlling interest
dilut ep report
premium fee
global care benefit expens
health care benefit expens settlement
total benefit expens
pharmaci cost good sold
total benefit expens
